Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Giiant pharma.

    Client Virtual Booth

    GIIANT PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Giiant pharma
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    1000 Rue De La Gauchetière O, Suite 2100, Montreal, Quebec H3B 4W5
    Telephone
    Telephone
    514 825-9035
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://giiant.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/giiantpharma/?originalSubdomain=ca
    Twitter
    Twitter
    https://twitter.com/giiant_pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108

    Details:

    The proceeds will be used for the development of Palisade's lead program, PALI-2108, a microbiota-activated PDE4 inhibitor prodrug, for the treatment of moderate-to-severe ulcerative colitis.


    Lead Product(s): PALI-2108

    Therapeutic Area: Gastroenterology Product Name: PALI-2108

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Crohn’s and Colitis Foundation

    Deal Size: $0.5 million Upfront Cash: Undisclosed

    Deal Type: Funding December 28, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates T...

    Details:

    Under the agreement, Palisade wil develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform, including GT-2108, an orally administered, gut-restricted, colon-specific PDE4 inhibitor prodrug in development for patients affected by ulcerative colitis.


    Lead Product(s): GT-2108

    Therapeutic Area: Gastroenterology Product Name: GT-2108

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Palisade Bio

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement September 06, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept

    Details:

    Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.


    Lead Product(s): GT-2108

    Therapeutic Area: Gastroenterology Product Name: GT-2108

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Amplitude Ventures

    Deal Size: $1.2 million Upfront Cash: Undisclosed

    Deal Type: Financing June 30, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Giiant Pharma inc Announced the Closing of US$11M in Seed Financing

    Details:

    The Company has identified GT-2108 as a lead candidate for the treatment of inflammatory bowel diseases (IBD). GT-2108 is an orally-administered, colon-specific PDE4 inhibitor prodrug with potent anti-inflammatory properties.


    Lead Product(s): GT-2108

    Therapeutic Area: Gastroenterology Product Name: GT-2108

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Amplitude Ventures

    Deal Size: $11.0 million Upfront Cash: Undisclosed

    Deal Type: Financing May 19, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search